Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Heidelberg Pharma AGWBO:HPHA 32 PS Ratio is 16.14 as of Jul. 16, 2026, which is 16% below its 10-year median of 19.15. GuruFocus rates WBO:HPHA with a GF Score™ of 32/100 and a GF Value™ of €2.87 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 930 Biotechnology companies, Heidelberg Pharma AG ranks worse than 75.59% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Heidelberg Pharma AG's share price is €2.55.
Heidelberg Pharma AG's Revenue per Share for the trailing twelve months (TTM) ended in May. 2026 was €0.16. Hence, Heidelberg Pharma AG's PS Ratio for today is 16.14.
Good Sign:
Heidelberg Pharma AG stock PS Ratio (=16.14) is close to 1-year low of 16.14.
The historical rank and industry rank for Heidelberg Pharma AG's PS Ratio or its related term are showing as below:
WBO:HPHA'
s PS Ratio Range Over the Past 10 Years
Min: 7.4 Med: 19.15 Max: 105.66
Current: 16.14
During the past 13 years, Heidelberg Pharma AG's highest PS Ratio was 105.66. The lowest was 7.40. And the median was 19.15.
WBO:HPHA's PS Ratio is ranked worse than 75.59% of 930
companies
in the Biotechnology industry
Industry Median: 9.655
vs WBO:HPHA: 16.14
Heidelberg Pharma AG revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Heidelberg Pharma AG was 75.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -60.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -22.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -5.90% per year.
During the past 13 years, Heidelberg Pharma AG's highest 3-Year average Revenue per Share Growth Rate was 39.60% per year. The lowest was -60.30% per year. And the median was -19.60% per year.
Back to Basics: PS Ratio
Heidelberg Pharma AG (WBO:HPHA) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Heidelberg Pharma AG PS Ratio Related Terms
Heidelberg Pharma AG PS Ratio Historical Data
* Premium members only.
The historical data trend for Heidelberg Pharma AG's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Heidelberg Pharma AG's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Heidelberg Pharma AG PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's PS Ratio distribution charts can be found below:
* The bar in red indicates where Heidelberg Pharma AG's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Heidelberg Pharma AG's Share Price of today is €2.55. Heidelberg Pharma AG's Revenue per Share for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.16.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Heidelberg Pharma AG (WBO:HPHA) has a PS Ratio of 16.14 as of Jul. 16, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Heidelberg Pharma AG and its competitors. This is 16% below median its historical median of 19.15. Over the past decade, Heidelberg Pharma AG's PS Ratio has ranged from 7.40 to 105.66. According to the industry distribution chart, Heidelberg Pharma AG ranks #703 out of 930 companies in the Biotechnology industry, placing it in the top 75.6%.
Is Heidelberg Pharma AG's PS Ratio too high?
Heidelberg Pharma AG's current PS Ratio of 16.14 is 16% below median its 10-year median of 19.15. Over the past 10 years, this metric has ranged from a low of 7.40 to a high of 105.66. The Biotechnology industry median PS Ratio is 9.66. Heidelberg Pharma AG's value of 16.14 is 67.2% above this industry median. Based on the distribution chart, Heidelberg Pharma AG ranks #703 out of 930 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Heidelberg Pharma AG has a GF Score™ of 32/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Heidelberg Pharma AG's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Heidelberg Pharma AG ranks #703 out of 930 companies for PS Ratio. This places Heidelberg Pharma AG in the lower half of its industry. The industry median PS Ratio is 9.66. Heidelberg Pharma AG's value of 16.14 is 67.2% above this benchmark. Historically, Heidelberg Pharma AG's own PS Ratio has ranged from 7.40 to 105.66 over the past decade. While the company's 10-year median is 19.15 vs. the industry median of 9.66, Heidelberg Pharma AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.66, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Heidelberg Pharma AG's current PS Ratio of 16.14 is 67.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Heidelberg Pharma AG and its competitors. For the Biotechnology industry, the median PS Ratio is 9.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Heidelberg Pharma AG's current PS Ratio is 16.14, which is 16% below median its own 10-year median of 19.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heidelberg Pharma AG stock overvalued right now?
Based on GuruFocus' analysis, Heidelberg Pharma AG (WBO:HPHA) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.87, compared to a current price of €2.55 — trading 11.1% below its estimated fair value. The current PS Ratio is 16.14, which is 16% below median its 10-year median of 19.15 and 67.2% above the Biotechnology industry median of 9.66. Heidelberg Pharma AG's overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Heidelberg Pharma AG (WBO:HPHA), the current PS Ratio is 16.14 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Heidelberg Pharma AG (WBO:HPHA) Overvalued in 2026?
Based on GuruFocus' analysis, Heidelberg Pharma AG stock appears to be undervalued.
The current stock price of €2.55 is trading 11.1% below its estimated GF Value™ of €2.87.
GuruFocus considers Heidelberg Pharma AG to be Modestly Undervalued.
Key valuation signals for WBO:HPHA:
PS Ratio: 16.14 (16% below median its 10-year median of 19.15)
GF Value™: €2.87 vs. price of €2.55 (11.1% below fair value)
Industry Position: 67.2% above the Biotechnology median (#703 of 930)
No single metric tells the full story. See the WBO:HPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
32GF Score
Get the complete analysis for WBO:HPHA
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:HPHA has been successfully added to your 
